Key facts
- Notable investors include MedTech Innovator, Arben Ventures, BioTools Innovator, AIN Ventures, Pundi AI Startup PitchFest — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ChemT Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for ChemT Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ChemT Biotechnology
Developer of an artificial intelligence-enabled virtual cell engineering tool designed for scalable and consistent biologics manufacturing. The company combines proprietary artificial intelligence models with small molecule discovery to enhance the performance of T cells, Chinese Hamster Ovary (CHO) cells, and other therapeutic cell types by increasing yield and quality while reducing reliance on traditional components, enabling research institutions to produce advanced biologics such as antibodies, messenger RNA, and cell therapies with greater efficiency and reliability.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2024
- Employees
- 10
- Website
- chemtbio.com/
- Ownership
- Privately Held (backing)
ChemT Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ChemT Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ChemT Biotechnology in its N-PORT filings yet. We sweep new filings monthly.